secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001093557-25-000050
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DexCom appoints Renée Galá, Jazz Pharmaceuticals COO, to board
--------------------------------------------------------------

- Renée Galá appointed to DexCom board effective March 6, 2025; term expires at the 2025 annual meeting.
- Galá currently serves as President and COO of Jazz Pharmaceuticals, with prior CFO roles at Jazz and Theravance Biopharma.
- Received an initial RSU grant with a fair value of $500,000, vesting annually over three years.
- Board determined Galá qualifies as an independent director under Nasdaq rules.
- Galá also eligible for a pro-rated annual director RSU grant of $56,986 around the 2025 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000050/0001093557-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000050/dxcm-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer